Effects of Adoptive Immunotherapy on T Cell Subsets of Peripheral Blood in Non-small Cell Lung Cancer Patients

WANG Tingting; WANG Yu; JIA Yunlong; WANG Xuexiao; WANG Jiali; LV Wei; DUAN Yuqing; LIU Lihua

doi:10.3971/j.issn.1000-8578.2015.04.006

Cancer Research on Prevention and Treatment > 2015 > 42(04): 345-349. > DOI: 10.3971/j.issn.1000-8578.2015.04.006

WANG Tingting, WANG Yu, JIA Yunlong, WANG Xuexiao, WANG Jiali, LV Wei, DUAN Yuqing, LIU Lihua. Effects of Adoptive Immunotherapy on T Cell Subsets of Peripheral Blood in Non-small Cell Lung Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2015, 42(04): 345-349. DOI: 10.3971/j.issn.1000-8578.2015.04.006

Citation:

PDF (1610 KB)

Effects of Adoptive Immunotherapy on T Cell Subsets of Peripheral Blood in Non-small Cell Lung Cancer Patients

Department of Biotherapy, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050035, China

More Information

Received Date: April 20, 2014
Revised Date: June 26, 2014

Graphical Abstract

Abstract

Abstract

Objective To investigate the effect of cytokine-induced killer(CIK) cells therapy on T cell subsets in the peripheral blood and general condition of non-small cell lung cancer (NSCLC) patients. Methods Peripheral blood mononuclear cells (PBMCs) were collected from the peripheral blood of NSCLC patients. CIK cells were expanded by classical protocol, re-infused to the patients once a day for 3 consecutive days. Before and after 3 courses of CIK cells therapy, the changes of T cell subsets were assessed by flow cytometry, and the difference of T cell subsets between patients and healthy subjects were analyzed. General condition of NSCLC patients was observed before and after the therapy. Results Compared with the control group, the expression of CD3⁺T cells, CD3⁺CD4⁺T cells, CD4⁺/CD8⁺ T cells in the peripheral blood of NSCLC patients were significantly decreased (P<0.05), the expression of CD3⁺CD8⁺T cells were significantly increased (P<0.05). After the CIK cells therapy, the expression of CD3⁺ T cells, CD3⁺CD4⁺ T cells, CD4⁺/CD8⁺ T cells were significantly increased (P<0.05); while the expression of CD3⁺CD8⁺ T cells were significantly decreased (P<0.05). Compared with the control group, the expression of CD3⁺ T cells and CD4⁺/CD8⁺ T cells were significantly decreased (P<0.05) after CIK cells therapy; the expression of CD3⁺CD4⁺ T cells and CD3⁺CD8⁺ T cells were increased (P>0.05). Tregs in NSCLC patients before CIK cells therapy were significantly increased compared with the control group (P<0.05), and Tregs in stage Ⅲ~Ⅳ patients were significantly higher than that in stage Ⅰ~ Ⅱ patients(P<0.05). After CIK cells therapy, Tregs in stage Ⅰ~ Ⅱ and stage Ⅲ~Ⅳ patients were significantly decreased compared with those before CIK cells therapy(P<0.05). After CIK cells therapy, Tregs in stage Ⅰ~ Ⅱ patients were significantly lower than that in the control group (P<0.05).Tregs in stage Ⅲ~Ⅳ patients were still higher than that in the control group(P>0.05). Conclusion CIK cells therapy could enhance the immunity, improve general condition and quality of life of NSCLC patients without obvious side effects.
- Cytokine-induced killer cells,
- Non-small cell lung cancer(NSCLC),
- Immunity,
- Regulatory Tcells

FullText(HTML)

References (18)

References

[1]	Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion[J]. Science, 2011, 331(6024): 1565-70．
[2]	Feliciano J, Feigenberg S, Mehta M. Chemoradiation for definitive, preoperative, or postoperative therapy of locally advanced nonsmall cell lung cancer[J]. Cancer J, 2013, 19(3): 222-30.
[3]	Urbanska K, Lanitis E, Poussin M, et al. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor[J]. Cancer Res, 2012, 72(7): 1844-52.
[4]	Andersen MH, Sørensen RB, Brimnes MK, et al. Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients[J]. J Clin Invest, 2009, 119(8): 2245-56.
[5]	Liu L, Zhang W, Qi X, et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma[J]. Clin Cancer Res, 2012, 18(6): 1751-9.
[6]	Li R, Wang C, Liu L, et al. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study[J]. Cancer Immunol Immunother, 2012, 61(11): 2125-33.
[7]	Shi M, Zhang B, Tang ZR, et al. Autologous cytokine-induced killer cell therapy in clinical trial phase Ι is safe in patients with primary hepatocellular carcinoma [J]. World J Gastroenterol, 20 04, 10(8):1146-51.
[8]	Shepherd FA, Douillard JY, Blumenschein GR Jr. Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome[J]. J Thorac Oncol, 2011, 6(10): 1763-73.
[9]	Broderick I, Yokota SJ, Reineke J, et al. Human CD4+ effector memory T cells persisting in the microenvironment of lung cancer xenografts are activated by local delivery of IL-12 to proliferate, produce IFN-gamma, and eradicate tumor cells[J]. J Immunol, 20 05, 174(2): 898-906.
[10]	Jin CG, Chen XQ, Li J, et al. Moderating effects and maintenance of lung cancer cellular immune functions by CIK cell therapy[J]. Asian Pac J Cancer Prev, 2013, 14(6): 3587-92.
[11]	Filaci G, Fenoglio D, Fravega M, et al. CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers[J]. J Immunol, 2007, 179(7): 4323-34.
[12]	Najafian N, Chitnis T, Salama AD, et al. Regulatory functions of CD8+CD28- T cells in an autoimmune disease model[J]. J Clin Invest, 2003, 112(7): 1037-48.
[13]	Yue Q, Zhang X, Ye HX, et al. The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma [J]. Neurooncol, 2014, 116(2): 251-9.
[14]	Wang LK, Kuang M, Hua YP, et al. Profile of regulatory T cells and interferon γ secretion in the tumor-draining lymph node from mouse Hepa1-6 cells[J]. J Surg Res, 2013, 183(2): 900-6.
[15]	Zou W. Regulatory T cells, tumour immunity and immunotherapy[J]. Nat Rev Immunol, 2006, 6(4): 295-307.
[16]	Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer[J]. Cancer Res, 2001, 61(12): 47 66-72.
[17]	Li H, Yu JP, Cao S, et al. CD4+CD25+ regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients[J]. J Clin Immunol, 2007, 27(3): 317-26.
[18]	Xu WL, Cai JH, Li SL, et al. Effect of interfering tumor microenvironment on homing and killilng activity of cytotoxic T lymphocytes[J]. Zhong Liu Fang Zhi Yan Jiu, 2014, 41(12): 12 86-91.[徐立伟, 蔡建辉, 李索林, 等. 干扰肿瘤微环境对细胞毒性T淋巴细胞瘤体内归巢和杀伤活性的影响[J]. 肿瘤防治研究, 20 14, 41(12): 1286-91.]

Cited By

Get Citation

PDF

XML

Article views (1191) PDF downloads (378)

Turn off MathJax

Article Contents

Abstract

References

Effects of Adoptive Immunotherapy on T Cell Subsets of Peripheral Blood in Non-small Cell Lung Cancer Patients

Abstract

References

Catalog

Download Center

Links

Contact Us

Effects of Adoptive Immunotherapy on T Cell Subsets of Peripheral Blood in Non-small Cell Lung Cancer Patients

Abstract

References

Catalog

Download Center

Links

Contact Us

Export File

Citation

Format

Content